INTRODUCTION

Chronic hyperglycemia, a contributing factor in diabetic vascular complications, has been evaluated through experimental and large-scale clinical studies, such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) [123]. A follow-up DCCT study found that when the regulation of blood glucose was controlled strictly for 6.5 years at the initial stage of type 1 diabetes mellitus (T1DM), the effect lasted so long that the progression of microvascular complications was delayed for at least 8 years after the termination of the initial study, and the occurrence of cardiovascular events was delayed for 11 years [2]. According to the UKPDS follow-up study, patients with type 2 diabetes mellitus (T2DM) also had the legacy effect stemming from the strict regulation of blood sugar from the initial stage of the disease, which suggests that the phenomenon of metabolic memory exists in the vascular complications of diabetes [3].

Recent studies have suggested that advanced glycation end-products (AGEs) may be a key factor in the development of metabolic memory in diabetic complications, because AGEs are produced and accumulated irreversibly in the body, depending on the degree of blood sugar regulation and duration [4]. Once produced, the material is metabolized so slowly that it can well explain the phenomenon of metabolic memory or legacy effect [5]. Direct evidence of the relationship between the accumulation of AGEs and development of diabetic vascular complications was reported recently [6].

In this review, we summarized the recent AGE-related updates that have an important influence on the occurrence and deterioration of these diabetic vascular complications.

ADVANCED GLYCATION END-PRODUCTS

AGEs are produced by the Maillard reaction. A reducing sugar, such as glucose, reacts non-enzymatically with the amino group of proteins to produce a Schiff base that rearranges into Amadori compounds [5]. These Amadori adducts then very slowly undergo irreversible dehydration and condensation reactions, eventually producing AGEs, which are yellowish-brown materials with particular fluorescence [5].

AGEs are produced not only from glucose but also from the dicarbonyl compound produced from autoxidation and the degradation products of glucose, such as glyoxal, methylglyoxal, and 3-deoxyglucosone, or α-hydroxy aldehydes such as glyceraldehyde and glycolaldehyde [78]. In the case of chronic hyperglycemia, AGEs are actively produced and accumulate in the circulating blood and various tissues, resulting in vascular complications in diabetes [5].

Although AGEs are produced endogenously by oxidative stress or hyperglycemia, they can be consumed exogenously through food. About 6% to 7% of AGEs derived from meals are known to be present in the body for a certain period of time [910].

AGE-RAGE SYSTEM IN DIABETIC VASCULAR COMPLICATIONS

AGEs accelerate the expression of receptors for advanced glycation end-products (RAGEs). The constant activation of the AGE-RAGE system is presumed to create the long-term metabolic memory or legacy effect [11]. Upon the recognition of AGEs by RAGE in endothelial cells, the production of oxidative stress is accelerated in the cells, and various cytokines and growth factors are secreted through the activation of nuclear factor κB, thereby inducing the expression of adhesion factor and causing an inflammatory response (Fig. 1) [12]. In patients with diabetes, RAGE expression is accelerated in atherosclerotic lesions in proportion to aggravation of blood sugar regulation [13].

The oxidative stress accelerated by AGE-RAGE inactivates nitric oxide and then either causes an inflammatory response or aggravates a thrombotic tendency that leads to the progression of arteriosclerosis [1415]. In endothelial cells, the AGE-RAGE system promotes the gene expression of p22^phox and gp91^phox, which are components of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, and accelerates the production of oxidative stress by activating the cell membrane transport of Rac family small GTPase 1 (Rac1) to cause endothelial cell dysfunction [16].

AGEs promote the production of vascular endothelial growth factor (VEGF) in the endothelial cells, which then induces pathological angiogenesis [17]. VEGF is known to be involved in the increasing atheroma in an atherosclerotic lesion [18]. This suggests that the AGE-RAGE system, through the production of VEGF, activates angiogenesis in atheroma and aggravates inflammation in the plaque, possibly by a hemorrhage or an increase in the atheroma [19].

In addition, the AGE-RAGE system inhibits the production of prostacyclin (PGI2) in endothelial cells and promotes the de novo synthesis of plasminogen activator inhibitor-1, thereby inhibiting fibrinolytic activity and then contributing to stabilization of the thrombus [19]. A decrease in cyclic adenosine monophosphate production through the AGE-RAGE system is expected to be involved in the thrombotic tendency [20].

AGEs are known to promote not only platelet aggregation but also the blood coagulation cascade through tissue factor production [21]. The thrombotic tendency induced by AGEs is considered the cause of acute coronary syndromes, such as unstable angina or acute myocardial infarction through atheroma rupture and subsequent thrombogenesis in the coronary artery [21].

The low density lipoproteins (LDLs) oxidized and denatured by AGEs are recognized by scavenger receptors, which then activate foam cell formation from macrophages and the secretion of chemokines or growth factors therein. The LDLs therefore accelerate the migration, proliferation, and transformation of smooth-muscle cells or the endothelial invasion by monocytes [22].

A clear progression of atherosclerosis and plaques accompanied by calcified lesions is observed in patients with diabetes [23]. In addition, the appearance of calcified lesions in atherosclerotic lesions is considered a predictive factor of future cardiovascular events and a marker of poor prognosis resistance to coronary intervention [23]. AGEs act on blood vessel wall cells, such as pericytes, promoting their differentiation into osteoblasts and thus causing calcification deposition [24]. Therefore, AGEs present in atherosclerotic lesions are presumed to be involved in the occurrence and progression of calcified lesions by acting on pericytes of the angiogenesis induced by an increase in atheroma [25].

AGE-RAGE SYSTEM WITH OTHER PATHWAYS

The oxidative stress accelerated by the AGE-RAGE system not only causes vascular disorder by activating the renin-angiotensin system (RAS) but also aggravates organ failure, because RAS activation causes NADPH oxidase-derived oxidative stress that again leads to an increase in RAGE expression as well as AGE production [2627]. This fact suggests that inhibition of the AGE-RAGE system is involved in some of the long-term protective effects of RAS inhibitors [27].

It is known that in hyperglycemia, the de novo synthesis of diacylglycerol is accelerated and protein kinase Cβ (PKCβ) is activated, and sorbitol or fructose is accumulated in the cells as a result of polyol pathway hyperactivity [28]. PKCβ activation is presumed to accelerate the activity of NADPH oxidase and then causes vascular complications in diabetes in connection with the AGE-RAGE system [28]. Fructose has a 10-time stronger glycation activity than glucose, and AGE formation from intracellular protein and fructose may be involved in vascular disorders [29]. The mitochondrial-derived oxidative stress produced by the hyperglycemic load causes AGE production, PKCβ activation, and polyol pathway hyperactivity [28]. These three hypotheses, which have existed for many years, and the AGE-RAGE system have a mutual role in the development of diabetic vascular complications [30].

AGE AND sRAGE AS INDICATORS OF VASCULAR COMPLICATIONS

Serum levels of AGEs are known to constitute an independent risk factor of endothelial dysfunction in patients with T2DM [4]. In addition, serum levels of AGEs were shown to be an independent factor for predicting death from cardiovascular events in women with T2DM or in nondiabetic patients in an 18-year follow-up study [30]. It is also known that serum AGE levels are related to left ventricular diastolic dysfunction and vascular stiffness in patients with T1DM [31].

RAGE has three splice variants of full-length RAGE, an N-terminal variant that does not contain an AGE-binding domain, a soluble receptor for advanced glycation end-product (sRAGE), and a C-terminal splice variant that does not include transmembrane and effector domains [32]. The physiological function of sRAGE has not yet been fully characterized, but it is known to be produced through cleavage of cell-surface RAGE and is known to reflect endothelial cell damage [33]. However, it is known that sRAGE can modulate the AGE-RAGE system as an antagonist of full-length RAGE [34].

Although serum levels of sRAGEs are only about 1/1,000 to 1/5,000 of the AGE concentrations in circulation, sRAGE could become an indicator for predicting the degree of vascular disorders because it reflects the RAGE expression in tissues [30]. One study also demonstrated that serum sRAGE levels were significantly higher in T2DM patients than in non-diabetic subjects and positively associated with the presence of coronary artery disease [33].

AGEs IN FOODS

Because the AGE reaction is also referred to as the browning reaction, the browning change of foods can be a measure of their AGE content. In general, it is known that a large amount of AGEs are produced when meats or fatty foods are heated or baked at a high temperature [35]. On the other hand, AGEs are not produced in a significant amount when foods are slowly steamed or heated with a lot of water for a long time [35]. For example, chicken shows a clear browning reaction, and grilled chicken skewers in particular have about 10 times higher levels of AGEs than chicken boiled in water [35].

Because assessments of their eating history and eating habits suggest a correlation between the amount of AGE intake and serum AGE level, a decrease in the amount of food-derived AGE intake is considered to inhibit vascular complications in diabetic patients [3536]. In this regard, some experiments also reported that the long-term consumption of AGE-limiting foods in mice reduced oxidative stress markers and inhibited insulin resistance and organ failure, resulting in an extension of life span [37]. Therefore, the limitation of food-derived AGEs can become a significant therapeutic target for inhibiting organ failure due to diabetes or aging.

Indeed, when patients with T2DM consumed AGE-restricted diet, the serum levels of AGEs decreased by around 30% to 40% in 2 to 6 weeks, resulting in a 20% decrease in markers of vascular complications, such as soluble vascular cell adhesion molecule-1 or C-reactive protein, or inflammatory markers [38]. In addition, it is known that in diabetic patients who limited food-derived AGEs, the AGE formation or oxidative degeneration of blood LDL-cholesterol is inhibited, and vascular complications due to LDL-cholesterol are also decreased [39]. However, it is not yet known whether the long-term, AGE-limiting diets can inhibit vascular complications in diabetic patients and improve their prognosis. In addition, differences in the absorption capacity of the gastrointestinal tract; the binding capacity with RAGE; and organ failure, depending on the type of AGEs taken up by the body, should be considered.

AGENTS KNOWN TO MODULATE AGEs

Several drugs are known to modulate AGEs (Table 1). Statin could slow the AGE-RAGE-mediated activation of NADPH oxidase by inhibiting the prenylation of Rac1, which subsequently inhibits post-RAGE-induced signal transduction [40]. Pravastatin is known to reduce tubular damage in diabetic nephropathy in tubular cells and attenuate AGEs-induced apoptosis [41]. Atorvastatin is also known to inhibit AGE formation through its anti-oxidative activity [42].

Telmisartan, an angiotensin receptor blocker with selective peroxisome proliferator-activated receptor γ activation, is known to inhibit RAGE expression in endothelial cells, renal mesangial cells, and hepatocytes [43]. It is known to inhibit the expression of oxidative stress and inflammatory markers by inhibiting signal transduction by AGEs and expression of arteriosclerosis-related genes [4344]. It is also known that ramipril, an angiotensin-converting enzyme inhibitor, can regulate AGEs with a similar mechanism of action [45].

The AGE modulatory potential is also known in some anti-diabetic medications. Rosiglitazone could reduce the expression of RAGE on the myocardium and attenuates cardiac fibrosis and ventricular diastolic function in experimental models [46]. Exendin-4 could inhibit the AGE-RAGE-mediated damage in tubular cells to attenuate the development and progression of diabetic nephropathy [47]. Linagliptin also has beneficial effects on diabetic nephropathy, partially inhibiting AGE-RAGE-evoked oxidative stress generation [4849].

Therefore, these agents are regarded as AGE-RAGE modulators in a broad sense. However, it is still unclear whether the modulation of AGEs by these drugs plays an important role in the improvement of diabetic macrovascular complications, compared to the main effects of these drugs.

Recently, the efficacy of aminoguanidine has been evaluated as a novel intervention for AGEs. Studies have shown that aminoguanidine inhibits the formation of AGEs and inhibits micro- and macrovascular complications in apolipoprotein knockout mice [505152]. It is also known that AGE cross-link breakers such as ALT-711 or alagebrium may help prevent diabetic vascular complications [4552]. In addition, the effect of direct antagonism on AGE of sRAGE has been demonstrated in some experimental studies [32]. However, the effect of the AGE modulator on advanced complications is unclear. In addition, there are few intervention studies of the actual clinical usefulness.

CONCLUSIONS

The formation of AGEs in diabetes patients occurs as a consequence of chronically elevated blood glucose levels. Some of the AGEs are known to be ingested through food. These AGEs could be one of the major contributing factors to the development of diabetic complications. It increases oxidative stress in the body according to various mechanisms and induces an inflammatory reaction, which has an important influence on the occurrence and exacerbation of diabetic vascular complications.

Recently, several clinical and preclinical studies have shown that interventions for these AGEs may play an important role in the reduction and prevention of diabetic vascular complications. This can be achieved not only by proper blood glucose control but also through diet and medical intervention. Recently, new compounds for the regulation of AGEs in the body have been studied.

In the future, further research results will clarify the role of AGEs in diabetic vascular complications, and we hope that successful intervention will help prevent complications and improve the quality of life for diabetic patients.

Acknowledgements

ACKNOWLEDGMENTS

Professor Young Seol Kim received the ninth Sulwon Award at the 2017 International Conference on Diabetes and Metabolism, September 28 to 30, 2017, at Seoul, Korea. The work was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare Republic of Korea (HI10C2020).

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

REFERENCES

• 1. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002;251:87-101. ArticlePubMed
• 2. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167. ArticlePubMedPMC
• 3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589. ArticlePubMed
• 4. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-146. ArticlePubMedPDF
• 5. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279-2299. ArticlePubMed
• 6. Koska J, Saremi A, Howell S, Bahn G, De Courten B, Ginsberg H, Beisswenger PJ, Reaven PD. VADT Investigators. Advanced glycation end products, oxidation products, and incident cardiovascular events in patients with type 2 diabetes. Diabetes Care 2018;41:570-576. ArticlePubMedPDF
• 7. Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J Biol Chem 1994;269:32299-32305. ArticlePubMed
• 8. Ahmed N, Thornalley PJ, Dawczynski J, Franke S, Strobel J, Stein G, Haik GM. Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. Invest Ophthalmol Vis Sci 2003;44:5287-5292. ArticlePubMed
• 9. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005;1043:461-466. ArticlePubMed
• 10. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007;13:2832-2836. ArticlePubMed
• 11. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37:586-600. ArticlePubMed
• 12. Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, Yan SF, Schmidt AM. RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 2004;24:1342-1349. PubMed
• 13. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000;2:430-436. ArticlePubMedPDF
• 14. Xu B, Ji Y, Yao K, Cao YX, Ferro A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin Sci (Lond) 2005;109:439-446. ArticlePubMedPDF
• 15. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432-438. ArticlePubMedPMC
• 16. Yamagishi S, Nakamura N, Suematsu M, Kaseda K, Matsui T. Advanced glycation end products: a molecular target for vascular complications in diabetes. Mol Med 2015;21(Suppl 1):S32-S40. ArticlePubMedPMCPDF
• 17. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 2001;276:43836-43841. ArticlePubMed
• 18. Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GY. Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart 2003;89:1411-1415. ArticlePubMedPMC
• 19. Yamagishi S, Adachi H, Takeuchi M, Enomoto M, Furuki K, Matsui T, Nakamura K, Imaizumi T. Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res 2007;39:845-848. ArticlePubMed
• 20. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011;46:217-224. ArticlePubMed
• 21. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014;18:1-14. ArticlePubMedPMC
• 22. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006;3:73-77. ArticlePubMed
• 23. Chait A, Bornfeldt KE. Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res 2009;50(Suppl):S335-S339. ArticlePubMedPMC
• 24. Wei Q, Ren X, Jiang Y, Jin H, Liu N, Li J. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress. BMC Cardiovasc Disord 2013;13:13. ArticlePubMedPMCPDF
• 25. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003;108:1070-1077. ArticlePubMed
• 26. Cheng CL, Tang Y, Zheng Z, Liu X, Ye ZC, Wang C, Lou TQ. Advanced glycation end-products activate the renin-angiotensin system through the RAGE/PI3-K signaling pathway in podocytes. Clin Invest Med 2012;35:E282. ArticlePubMedPDF
• 27. Geronikaki A, Gavalas A, Dislian V, Giannoglou G. Inhibition of renin-angiotensin system and advanced glycation end products formation: a promising therapeutic approach targeting on cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 2007;5:249-264. ArticlePubMed
• 28. Gleissner CA, Galkina E, Nadler JL, Ley K. Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today Dis Mech 2007;4:131-140. ArticlePubMedPMC
• 29. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 2008;14:487-495. ArticlePubMed
• 30. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Imaizumi T. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007;13:185-189. ArticlePubMedPMCPDF
• 31. Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, Hanssen KF. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999;22:1186-1190. ArticlePubMedPDF
• 32. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370(Pt 3):1097-1109. ArticlePubMedPMCPDF
• 33. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007;23:368-371. ArticlePubMed
• 34. Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, Reinhart TA, Oury TD. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2004;279:50019-50024. ArticlePubMed
• 35. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, Yong A, Striker GE, Vlassara H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010;110:911-916. ArticlePubMedPMC
• 36. Luevano-Contreras C, Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients 2010;2:1247-1265. ArticlePubMedPMC
• 37. Liu G, Zong G, Hu FB, Willett WC, Eisenberg DM, Sun Q. Cooking methods for red meats and risk of type 2 diabetes: a prospective study of U.S. Women. Diabetes Care 2017;40:1041-1049. ArticlePubMedPMCPDF
• 38. Luevano-Contreras C, Garay-Sevilla ME, Wrobel K, Malacara JM, Wrobel K. Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J Clin Biochem Nutr 2013;52:22-26. ArticlePubMed
• 39. Wu CH, Huang SM, Lin JA, Yen GC. Inhibition of advanced glycation endproduct formation by foodstuffs. Food Funct 2011;2:224-234. ArticlePubMed
• 40. Kwok JM, Ma CC, Ma S. Recent development in the effects of statins on cardiovascular disease through Rac1 and NADPH oxidase. Vascul Pharmacol 2013;58:21-30. ArticlePubMed
• 41. Ishibashi Y, Yamagishi S, Matsui T, Ohta K, Tanoue R, Takeuchi M, Ueda S, Nakamura K, Okuda S. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism 2012;61:1067-1072. ArticlePubMed
• 42. Yamagishi S. Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA. Eur Heart J 2008;29:1922.Article
• 43. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007;7:463-469. PubMed
• 44. Yamagishi S, Nakamura K, Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol Res 2009;60:174-178. ArticlePubMed
• 45. Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, Arnstein M, Thorpe SR, Cooper ME, Forbes JM. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 2007;148:886-895. ArticlePubMed
• 46. Ihm SH, Chang K, Kim HY, Baek SH, Youn HJ, Seung KB, Kim JH. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor. Basic Res Cardiol 2010;105:399-407. ArticlePubMedPDF
• 47. Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M, Fukami K, Yamagishi S. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol 2013;182:132-141. ArticlePubMed
• 48. Nakashima S, Matsui T, Takeuchi M, Yamagishi SI. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res 2014;46:717-721. ArticlePubMed
• 49. Matsui T, Nakashima S, Nishino Y, Ojima A, Nakamura N, Arima K, Fukami K, Okuda S, Yamagishi S. Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Lab Invest 2015;95:525-533. ArticlePubMedPDF
• 50. Thornalley PJ, Yurek-George A, Argirov OK. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 2000;60:55-65. PubMed
• 51. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40:1328-1334. ArticlePubMedPDF
• 52. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:1813-1823. ArticlePubMedPDF

Fig. 1

Suggested mechanism of advanced glycation end-products (AGEs) in diabetic vascular complications. RAGE, receptor for advanced glycation end-product; NF-κB, nuclear factor κB; RAS, renin-angiotensin system; TZD, thiazolidinediones; GLP-1, glucagon like peptide-1; DPP-4, dipeptidylpeptide-4; sRAGE, soluble receptor for advanced glycation end-product; ROS, reactive oxygen species; eNOS, endothelial nitric oxide synthase; NADPH, nicotinamide adenine dinucleotide phosphate; IL, interleukin; TNF-α, tumor necrosis factor α.

Table 1

Agents known to modulate AGEs

Agents	Suggested effects	References
Pravastatin	Reduce tubular damage in diabetic nephropathy in tubular cells and attenuate AGEs-induced apoptosis	[41]
Atorvastatin	Inhibit AGE formation through its anti-oxidative activity	[42]
Telmisartan	Inhibit the expression of oxidative stress and inflammatory markers by inhibiting signal transduction by AGEs and expression of arteriosclerosis-related genes	[43,44]
Ramipril	Inhibit the expression of oxidative stress and inflammatory markers by inhibiting signal transduction by AGEs	[45]
Rosiglitazone	Reduce the expression of RAGE on the myocardium and attenuate cardiac fibrosis and ventricular diastolic function	[46]
Exendin-4	Inhibit the AGE-RAGE mediated damage in tubular cells to attenuate the development and progression of diabetic nephropathy	[47]
Linagliptin	Inhibit AGE-RAGE–evoked oxidative stress generation	[48,49]
Aminoguanidine	Prevent cardiac hypertrophy and arterial stiffening in diabetic cardiomyopathy	[50,51,52]
ALT-711	AGE cross-link breaker	[52]
Alagebrium	AGE cross-link breaker	[45]
sRAGE	Competitive inhibitor of RAGE	[32]

AGE, advanced glycation end-product; RAGE, receptor for advanced glycation end-product; sRAGE, soluble receptor for advanced glycation end-product.

Figure & Data

References

Citations

Citations to this article as recorded by  

• Binding of RAGE and RIPK1 induces cognitive deficits in chronic hyperglycemia‐derived neuroinflammation
  Xiaoyan Zhou, Yandong Zhu, Lin Gao, Yan Li, Hui Li, Chengyu Huang, Yan Liu, Ankang Hu, Changjiang Ying, Yuanjian Song
  CNS Neuroscience & Therapeutics.2024;[Epub]     CrossRef
• Homeopathic Formulations of Syzygium jambolanum Alleviate Glycation-Mediated Structural and Functional Modifications of Albumin: Evaluation through Multi-Spectroscopic and Microscopic Approaches
  Nilima S. Bangar, Selvan Ravindran, Shamim A. Shaikh, Nilesh Shah, Rashmi S. Tupe
  Homeopathy.2024; 113(02): 098.     CrossRef
• Emerging roles of microRNAs as diagnostics and potential therapeutic interest in type 2 diabetes mellitus
  Dharmsheel Shrivastav, Desh Deepak Singh
  World Journal of Clinical Cases.2024; 12(3): 525.     CrossRef
• Unraveling the Link between Ιnsulin Resistance and Bronchial Asthma
  Konstantinos Bartziokas, Andriana I. Papaioannou, Fotios Drakopanagiotakis, Evanthia Gouveri, Nikolaos Papanas, Paschalis Steiropoulos
  Biomedicines.2024; 12(2): 437.     CrossRef
• Cerebral arteriolosclerosis, lacunar infarcts, and cognition in older Black adults
  Debra A. Fleischman, Konstantinos Arfanakis, Sue E. Leurgans, Zoe Arvanitakis, Melissa Lamar, S. Duke Han, Victoria N. Poole, David A. Bennett, Lisa L. Barnes
  Alzheimer's & Dementia.2024; 20(8): 5375.     CrossRef
• Advancements in diabetic foot ulcer research: Focus on mesenchymal stem cells and their exosomes
  ShuHui Wu, ZhongSheng Zhou, Yang Li, Jinlan Jiang
  Heliyon.2024; 10(17): e37031.     CrossRef
• Modulatory Effects of 830 nm on Diabetic Wounded Fibroblast Cells: An In Vitro Study on Inflammatory Cytokines
  Tintswalo Nomsa Mgwenya, Heidi Abrahamse, Nicolette Nadene Houreld
  Photobiomodulation, Photomedicine, and Laser Surgery.2024;[Epub]     CrossRef
• Effect of Extraction Methods on Chemical Characteristics and Bioactivity of Chrysanthemum morifolium cv. Fubaiju Extracts
  Shang Gao, Tiantian Li, Zhao-Rong Li, Bingwu Liao, Zirui Huang, Chunxia Zhou, Rui-Bo Jia
  Foods.2024; 13(19): 3057.     CrossRef
• Comparison of metabolic fate, target organs, and microbiota interactions of free and bound dietary advanced glycation end products
  Xiaojin Yuan, Chenxi Nie, Huicui Liu, Qingyu Ma, Bo Peng, Min Zhang, Zhifei Chen, Juxiu Li
  Critical Reviews in Food Science and Nutrition.2023; 63(19): 3612.     CrossRef
• Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes
  Savita Bansal, Archana Burman, Asok Kumar Tripathi
  World Journal of Diabetes.2023; 14(8): 1146.     CrossRef
• Potential roles of ellagic acid on metabolic variables in diabetes mellitus: A systematic review
  Vahid Maleki, Sepideh Abbaszadeh, Seyyed Morteza Seyyed Shoura, Asma Sohrabnavi, Mojtaba Sepandi, Maryam Taghdir
  Clinical and Experimental Pharmacology and Physiology.2023; 50(2): 121.     CrossRef
• Piperine mitigates aortic vasculopathy in streptozotocin-diabetic rats via targeting TXNIP-NLRP3 signaling
  Fatma M. Amin, George S.G. Shehatou, Manar A. Nader, Rania R. Abdelaziz
  Life Sciences.2023; 314: 121275.     CrossRef
• Endothelial-to-mesenchymal transition: An underappreciated mediator of diabetic complications
  Eric Wang, Honglin Wang, Subrata Chakrabarti
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Detection of Advanced Glycosylation End Products in the Cornea Based on Molecular Fluorescence and Machine Learning
  Jianming Zhu, Sifeng Lian, Haochen Zhong, Ruiyang Sun, Zhenbang Xiao, Hua Li
  Biosensors.2023; 13(2): 170.     CrossRef
• DF-5 COMPOUND DELAYS DEVELOPMENT OF DIABETIC NEPHROPATHY IN RATS
  A. A. Spasov, O. N. Zhukovskaya, A. I. Rashchenko, A. A. Brigadirova, R. A. Litvinov, N. A. Gurova, A. V. Smirnov, N. G. Pan’shin, H. S.A. Abbas, A. S. Morkovnik
  Pharmacy & Pharmacology.2023; 10(6): 549.     CrossRef
• Dietary advanced glycation end products (dAGEs): An insight between modern diet and health
  Zhaoqing Tian, Shasha Chen, Yiheng Shi, Panpan Wang, Yongning Wu, Guoliang Li
  Food Chemistry.2023; 415: 135735.     CrossRef
• Predictive Value of Noninvasive Peripheral Atherosclerosis Measurement for Coronary Artery Disease in Patients with Long T2DM Duration
  Wanjiao Chen, Li Wang, Bin Hu, Ying Zheng, Shuya Zhang, Zhong Zhou, Yifeng Mai
  Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 1075.     CrossRef
• Cereal polyphenols inhibition mechanisms on advanced glycation end products and regulation on type 2 diabetes
  Lezhen Dong, Ying Li, Qin Chen, Yahui Liu, Zufang Wu, Daodong Pan, Ning Yan, Lianliang Liu
  Critical Reviews in Food Science and Nutrition.2023; : 1.     CrossRef
• Artemisinin attenuates type 2 diabetic cardiomyopathy in rats through modulation of AGE-RAGE/HMGB-1 signaling pathway
  Eman A. E. Farrag, Maha O. Hammad, Sally M. Safwat, Shereen Hamed, Doaa Hellal
  Scientific Reports.2023;[Epub]     CrossRef
• Glycemic Control and Adverse Clinical Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: Results from KNOW-CKD
  Ga Young Heo, Hee Byung Koh, Hyung Woo Kim, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Jayoun Kim, Soo Wan Kim, Yeong Hoon Kim, Su Ah Sung, Kook-Hwan Oh, Seung Hyeok Han
  Diabetes & Metabolism Journal.2023; 47(4): 535.     CrossRef
• Chronic sildenafil citrate use decreases retinal vascular endothelial growth factor expression in diabetic rats: a pilot study
  Osama A. Sorour, Elsayed Nassar, Naglaa Sarhan, Noha El-Anwar, Reem A ElKholy, Dina M. Tahoon, Aalaa Sweilam, Dina Tadros
  International Journal of Retina and Vitreous.2023;[Epub]     CrossRef
• Pathophysiology of diabetic kidney disease and autophagy: A review
  Jiawei Yu, Yan Liu, Hongjie Li, Peirong Zhang
  Medicine.2023; 102(30): e33965.     CrossRef
• Evidence that methylglyoxal and receptor for advanced glycation end products are implicated in bladder dysfunction of obese diabetic ob/ob mice
  Akila L. Oliveira, Matheus L. Medeiros, Ana Carolina Ghezzi, Gabriel Alonso dos Santos, Glaucia Coelho Mello, Fabíola Z. Mónica, Edson Antunes
  American Journal of Physiology-Renal Physiology.2023; 325(4): F436.     CrossRef
• Effects of Advanced Glycation End Products via Oxidative Stress on Beta Cells: Insights from in vitro and in vivo Studies and Update on Emerging Therapies
  Ioanna A. Anastasiou, Konstantinos N. Tentolouris, Vaia Lambadiari, Ioanna Eleftheriadou, Maria Tektonidou, Nikolaos Tentolouris
  Mini-Reviews in Medicinal Chemistry.2023; 23(21): 2041.     CrossRef
• Insights into COVID-19 in age-related macular degeneration
  Rogil Jose de Almeida Torres
  The Pan-American Journal of Ophthalmology.2023;[Epub]     CrossRef
• Carvedilol improves heart rate variability indices, biomarkers but not cardiac nerve density in streptozotocin-induced T2DM model of diabetic cardiac autonomic neuropathy
  Olawale Mathias Akinlade, Bamidele Owoyele, Olufemi Ayodele Soladoye
  Journal of Basic and Clinical Physiology and Pharmacology.2022; 33(2): 213.     CrossRef
• Cerebral small vessel disease: A glymphopathy?
  Helene Benveniste, Maiken Nedergaard
  Current Opinion in Neurobiology.2022; 72: 15.     CrossRef
• Impact of glucose variability on coronary plaque vulnerability in patients with dysglycemia: A whole coronary analysis with multislice computed tomography
  Tsuyoshi Ito, Kosuke Nakasuka, Hiroshi Fujita, Masashi Yokoi, Takafumi Nakayama, Tomonori Sugiura, Nobuyuki Ohte, Yoshihiro Seo
  Journal of Cardiology.2022; 79(1): 58.     CrossRef
• Inhibition of Advanced Glycation End Product Formation in Rat Tail Tendons by Polydatin and p-Coumaric acid: an In Vitro Study
  Gopika Selvakumar, Dhanalakshmi Venu, Iyappan Kuttalam, Suguna Lonchin
  Applied Biochemistry and Biotechnology.2022; 194(1): 339.     CrossRef
• Anti-α-Glucosidase and Antiglycation Activities of α-Mangostin and New Xanthenone Derivatives: Enzymatic Kinetics and Mechanistic Insights through In Vitro Studies
  Francine Medjiofack Djeujo, Valeria Francesconi, Maddalena Gonella, Eugenio Ragazzi, Michele Tonelli, Guglielmina Froldi
  Molecules.2022; 27(2): 547.     CrossRef
• Metabolic and Metabo-Clinical Signatures of Type 2 Diabetes, Obesity, Retinopathy, and Dyslipidemia
  Noha A. Yousri, Karsten Suhre, Esraa Yassin, Alya Al-Shakaki, Amal Robay, Maha Elshafei, Omar Chidiac, Steven C. Hunt, Ronald G. Crystal, Khalid A. Fakhro
  Diabetes.2022; 71(2): 184.     CrossRef
• An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy
  Zunaira Qureshi, Murtaza Najabat Ali, Minahil Khalid, Nikolaos Papanas
  Journal of Diabetes Research.2022; 2022: 1.     CrossRef
• Glycation
  Sneha B. Bansode, Rakesh S. Joshi, Ashok P. Giri, Mahesh J. Kulkarni
  Chronicle of Diabetes Research and Practice.2022; 1(1): 31.     CrossRef
• Controlled Formation of Pyrazines: Inhibition by Ellagic Acid Interaction with N-(1-Deoxy-d-xylulos-1-yl)-glycine and Promotion through Ellagic Acid Oxidation
  Ziyan Wang, Heping Cui, Mengyu Ma, Khizar Hayat, Xiaoming Zhang, Chi-Tang Ho
  Journal of Agricultural and Food Chemistry.2022; 70(5): 1618.     CrossRef
• The Role of AGE-RAGE Signalling as a Modulator of Gut Permeability in Diabetes
  Matthew Snelson, Elisa Lucut, Melinda T. Coughlan
  International Journal of Molecular Sciences.2022; 23(3): 1766.     CrossRef
• Inhibition on α-Glucosidase Activity and Non-Enzymatic Glycation by an Anti-Oxidative Proteoglycan from Ganoderma lucidum
  Ying Zhang, Yanna Pan, Jiaqi Li, Zeng Zhang, Yanming He, Hongjie Yang, Ping Zhou
  Molecules.2022; 27(5): 1457.     CrossRef
• Alterations in pro- and anti-inflammatory mediators are involved in microvascular dysfunction in postmenopausal women with type 2 diabetes mellitus
  A.P. Jarrete, L.T. Giollo-Junior, J.F. Vilela-Martin, I.P. Novais, M.A. Delbin, A. Zanesco
  Brazilian Journal of Medical and Biological Research.2022;[Epub]     CrossRef
• Is dietary intake of advanced glycation end products associated with mortality among adults with diabetes?
  Alain K. Koyama, Meda E. Pavkov, Yanjue Wu, Karen R. Siegel
  Nutrition, Metabolism and Cardiovascular Diseases.2022; 32(6): 1402.     CrossRef
• Antidiabetic and antiglycating potential of chrysin is enhanced after nano formulation: An in vitro approach
  Asimah Khalid, Imrana Naseem
  Journal of Molecular Structure.2022; 1261: 132906.     CrossRef
• The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases
  Mieke Steenbeke, Reinhart Speeckaert, Stéphanie Desmedt, Griet Glorieux, Joris R. Delanghe, Marijn M. Speeckaert
  International Journal of Molecular Sciences.2022; 23(7): 3439.     CrossRef
• Nɛ-(carboxymethyl)lysine, Available Lysine, and Volatile Compound Profile of Biscuits Enriched with Grape by-Product During Storage
  Sylwia Mildner-Szkudlarz, Aleksander Siger, Krzysztof Przygoński, Elżbieta Radziejewska-Kubzdela, Renata Zawirska-Wojtasiak
  Plant Foods for Human Nutrition.2022; 77(2): 190.     CrossRef
• Chlorophytum alismifolium mitigates microvascular complications of type 2 diabetes mellitus: the involvement of oxidative stress and aldose reductase
  Abdulhakim Abubakar, Abdullahi Balarabe Nazifi, Idris Mohammed Maje, Yusuf Tanko, Joseph Akpojo Anuka, Ezzeldin Mukthar Abdurahman
  Drug Metabolism and Personalized Therapy.2022; 37(1): 69.     CrossRef
• A brief review of vitamin D as a potential target for the regulation of blood glucose and inflammation in diabetes-associated periodontitis
  Cheng Dong, Xuzhi Hu, Alok Shiomurti Tripathi
  Molecular and Cellular Biochemistry.2022; 477(9): 2257.     CrossRef
• Cerebral Microvascular Senescence and Inflammation in Diabetes
  Ashley Phoenix, Raghavendar Chandran, Adviye Ergul
  Frontiers in Physiology.2022;[Epub]     CrossRef
• Effects of natural dihydrochalcones in sweet tea (Lithocarpus polystachyus) on diabetes: a systematical review and meta-analysis of animal studies
  Xue-Min Chen, Wei-Qi Yang, Xue Wang, Chong Chen, Zheng-Ming Qian, Shu-Mei Wang, Dan Tang
  Food & Function.2022; 13(11): 5899.     CrossRef
• Investigation of DHA-Induced Regulation of Redox Homeostasis in Retinal Pigment Epithelium Cells through the Combination of Metabolic Imaging and Molecular Biology
  Giada Bianchetti, Maria Elisabetta Clementi, Beatrice Sampaolese, Cassandra Serantoni, Alessio Abeltino, Marco De Spirito, Shlomo Sasson, Giuseppe Maulucci
  Antioxidants.2022; 11(6): 1072.     CrossRef
• Almond and date fruits enhance antioxidant status and have erectogenic effect: Evidence from in vitro and in vivo studies
  Adeniyi A. Adebayo, Ganiyu Oboh, Ayokunle O. Ademosun
  Journal of Food Biochemistry.2022;[Epub]     CrossRef
• Inside the diabetic brain: Insulin resistance and molecular mechanism associated with cognitive impairment and its possible therapeutic strategies
  Bhaskar Jyoti Dutta, Shamsher Singh, Sanket Seksaria, Ghanshyam Das Gupta, Amrita Singh
  Pharmacological Research.2022; 182: 106358.     CrossRef
• Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus
  Jeongmin Lee, Jae-Seung Yun, Seung-Hyun Ko
  Nutrients.2022; 14(15): 3086.     CrossRef
• Interaction behavior between glycated human serum albumin and metformin in the presence of silver nanoparticles: a combination study of spectroscopic, calorimetric and molecular dynamic
  Sara Ezazi-Toroghi, Sana Abdul-Jabbar Ali, Dmitry Olegovich Bokov, Maryam Dareini, Malihe Bahadori, Parisa Mokaberi, Zeinab Amiri-Tehranizadeh, Mohammad Reza Saberi, Jamshidkhan Chamani
  Journal of the Iranian Chemical Society.2022; 19(12): 4569.     CrossRef
• The AGEs/RAGE Transduction Signaling Prompts IL-8/CXCR1/2-Mediated Interaction between Cancer-Associated Fibroblasts (CAFs) and Breast Cancer Cells
  Maria Francesca Santolla, Marianna Talia, Francesca Cirillo, Domenica Scordamaglia, Salvatore De Rosis, Asia Spinelli, Anna Maria Miglietta, Bruno Nardo, Gianfranco Filippelli, Ernestina Marianna De Francesco, Antonino Belfiore, Rosamaria Lappano, Marcell
  Cells.2022; 11(15): 2402.     CrossRef
• Association study of HIF-1α rs11549465 and VEGF rs3025039 genetic variants with diabetic retinopathy in Egyptian patients: crosslinks with angiogenic, inflammatory, and anti-inflammatory markers
  Mahmoud K. Mohamed, Azza A. Atef, Leqaa A. Moemen, Amira A. Abdel Azeem, Islam A. Mohalhal, Alshaimaa M. Taha
  Journal of Genetic Engineering and Biotechnology.2022; 20(1): 122.     CrossRef
• The association between advanced glycation end products (AGEs) and ABC (hemoglobin A1C, blood pressure, and low-density lipoprotein cholesterol) control parameters among patients with type 2 diabetes mellitus
  Mohaddeseh Rezaei, Soghra Rabizadeh, Maryam Mirahmad, Minoo Sadat Hajmiri, Manouchehr Nakhjavani, Mahboobeh Hemmatabadi, Nooshin Shirzad
  Diabetology & Metabolic Syndrome.2022;[Epub]     CrossRef
• Endogenous advanced glycation end products in the pathogenesis of chronic diabetic complications
  Misganaw Asmamaw Mengstie, Endeshaw Chekol Abebe, Awgichew Behaile Teklemariam, Anemut Tilahun Mulu, Melaku Mekonnen Agidew, Muluken Teshome Azezew, Edgeit Abebe Zewde, Assefa Agegnehu Teshome
  Frontiers in Molecular Biosciences.2022;[Epub]     CrossRef
• Antiglycation potential of plant based TiO2 nanoparticle in D‐ribose glycated BSA in vitro
  Fahaad Alenazi, Mohd Saleem, Azharuddin Sajid Syed Khaja, Mubashir Zafar, Mohammed Salem Alharbi, Turki Al Hagbani, Mohd Yasir Khan, Waseem Ahmad, Saheem Ahmad
  Cell Biochemistry and Function.2022; 40(7): 784.     CrossRef
• PECULIARITIES OF SYSTEMIC PATHOBIOCHEMICAL REACTIONS TO BRAIN ISCHEMIA-REPERFUSION IN RATS WITH DIABETES MELLITUS
  О.V. Tkachuk, S.S. Tkachuk, М.А. Povar, S.I. Anokhina, O.V. Yasinska, S.N. Vadziuk
  Fiziolohichnyĭ zhurnal.2022; 68(4): 40.     CrossRef
• Impact of High Aspartame and High Fructose Diet on Vascular Reactivity, Glucose Metabolism and Liver Structure in Diabetic Rats
  Adel Shalaby, Marwa Al-Gholam, Safa Elfiky, Ghada Elgarawany
  Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 1433.     CrossRef
• KITLG Promotes Glomerular Endothelial Cell Injury in Diabetic Nephropathy by an Autocrine Effect
  Jiun-Chi Huang, Szu-Chia Chen, Wei-An Chang, Wei-Wen Hung, Ping-Hsun Wu, Ling-Yu Wu, Jer-Ming Chang, Ya-Ling Hsu, Yi-Chun Tsai
  International Journal of Molecular Sciences.2022; 23(19): 11723.     CrossRef
• Comparative Evaluation of the Antiglycation and Anti-α-Glucosidase Activities of Baicalein, Baicalin (Baicalein 7-O-Glucuronide) and the Antidiabetic Drug Metformin
  Guglielmina Froldi, Francine Medjiofack Djeujo, Nadia Bulf, Emma Caparelli, Eugenio Ragazzi
  Pharmaceutics.2022; 14(10): 2141.     CrossRef
• Reduced coupling between the global blood-oxygen-level-dependent signal and cerebrospinal fluid inflow is associated with the severity of small vessel disease
  Yao Zhang, Ruiting Zhang, Shuyue Wang, Hui Hong, Yeerfan Jiaerken, Kaicheng Li, Qingze Zeng, Xiao Luo, Xinfeng Yu, Minming Zhang, Peiyu Huang
  NeuroImage: Clinical.2022; 36: 103229.     CrossRef
• To Investigate the Protective Effect and Mechanism of Isoorientin on Aortic in T2DM Macrovascular Disease Mice
  娟 谭
  Advances in Clinical Medicine.2022; 12(10): 9140.     CrossRef
• Low grade intravascular hemolysis associates with peripheral nerve injury in type 2 diabetes
  Sylvain Le Jeune, Sihem Sadoudi, Dominique Charue, Salwa Abid, Jean-Michel Guigner, Dominique Helley, Hélène Bihan, Camille Baudry, Hélène Lelong, Tristan Mirault, Eric Vicaut, Robin Dhote, Jean-Jacques Mourad, Chantal M. Boulanger, Olivier P. Blanc-Brude
  PLOS ONE.2022; 17(10): e0275337.     CrossRef
• Vascular contributions to cognitive impairment/dementia in diabetes: role of endothelial cells and pericytes
  Mia Edgerton-Fulton, Adviye Ergul
  American Journal of Physiology-Cell Physiology.2022; 323(4): C1177.     CrossRef
• The Potential Effect of Sildenafil Citrate on Some Hematological and Biochemical Parameters in Hyperglycemic Rats
  Khulood Hussein
  Pharmacophore.2022; 13(3): 98.     CrossRef
• Aqueous extract of Massularia acuminata exerts erectogenic effect by modulating critical enzymes and hormones in streptozotocin‐induced erectile dysfunction in rats
  Stephen Adeniyi Adefegha, Ganiyu Oboh, Abraham Olanrewaju Adedipe
  Andrologia.2022;[Epub]     CrossRef
• The Synthetic Flavonoid Hidrosmin Improves Endothelial Dysfunction and Atherosclerotic Lesions in Diabetic Mice
  Luna Jiménez-Castilla, Lucas Opazo-Ríos, Gema Marin-Royo, Macarena Orejudo, Raquel Rodrigues-Diez, Constanza Ballesteros-Martínez, Manuel Soto-Catalán, Teresa Caro-Ordieres, Inés Artaiz, Tatiana Suarez-Cortés, Arturo Zazpe, Gonzalo Hernández, Marcelino Co
  Antioxidants.2022; 11(12): 2499.     CrossRef
• Protective effects of Vitex pseudo-negundo leaves on diabetic-induced nephropathy in rats
  Hasan Rezaei Seresht, Esrafil Mansouri, Mahsa Daei Milani, Bahareh Vahidiyanfar, Arash Ramezanpour Shahi, Mohammad Javad Namazi, Hossein Moallaei, Maryam Latifnia, Mojtaba Fattahi Abdizadeh
  Journal of Basic and Clinical Physiology and Pharmacology.2021;[Epub]     CrossRef
• Oxidative stress mitigation by antioxidants - An overview on their chemistry and influences on health status
  Aurelia Magdalena Pisoschi, Aneta Pop, Florin Iordache, Loredana Stanca, Gabriel Predoi, Andreea Iren Serban
  European Journal of Medicinal Chemistry.2021; 209: 112891.     CrossRef
• Diabetes, insulin resistance, and asthma: a review of potential links
  Tianshi David Wu
  Current Opinion in Pulmonary Medicine.2021; 27(1): 29.     CrossRef
• Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease
  Alessandro Ciavarella, Davide Gnocchi, Carlo Custodero, Gennaro Mariano Lenato, Giorgio Fiore, Carlo Sabbà, Antonio Mazzocca
  Thrombosis Research.2021; 198: 139.     CrossRef
• A review on mechanism of inhibition of advanced glycation end products formation by plant derived polyphenolic compounds
  Shehwaz Anwar, Shifa Khan, Ahmad Almatroudi, Amjad Ali Khan, Mohammed A. Alsahli, Saleh A. Almatroodi, Arshad Husain Rahmani
  Molecular Biology Reports.2021; 48(1): 787.     CrossRef
• Acetoacetate enhancement of glucose mediated DNA glycation
  M. Bagherzadeh-Yazdi, M. Bohlooli, M. Khajeh, F. Ghamari, M. Ghaffari-Moghaddam, N. Poormolaie, A. Khatibi, P. Hasanein, N. Sheibani
  Biochemistry and Biophysics Reports.2021; 25: 100878.     CrossRef
• Macrophage inflammatory state in Type 1 diabetes: triggered by NLRP3/iNOS pathway and attenuated by docosahexaenoic acid
  Mariana Rodrigues Davanso, Amanda Rabello Crisma, Tárcio Teodoro Braga, Laureane Nunes Masi, Cátia Lira do Amaral, Vinícius Nunes Cordeiro Leal, Dhêmerson Souza de Lima, Thiago Andrade Patente, José Alexandre Barbuto, Maria L. Corrêa-Giannella, Mario Laut
  Clinical Science.2021; 135(1): 19.     CrossRef
• Model studies of advanced glycation end product modification of heterograft biomaterials: The effects of in vitro glucose, glyoxal, and serum albumin on collagen structure and mechanical properties
  Christopher A. Rock, Samuel Keeney, Andrey Zakharchenko, Hajime Takano, David A. Spiegel, Abba M. Krieger, Giovanni Ferrari, Robert J. Levy
  Acta Biomaterialia.2021; 123: 275.     CrossRef
• Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression
  C.M. Mosterd, M. Kanbay, B.J.H. van den Born, D.H. van Raalte, E. Rampanelli
  Best Practice & Research Clinical Endocrinology & Metabolism.2021; 35(3): 101484.     CrossRef
• Attenuation of protein glycation by functional polyphenolics of dragon fruit (Hylocereus polyrhizus); an in vitro and in silico evaluation
  Guna Ravichandran, Dinesh Kumar Lakshmanan, Selvakumar Murugesan, Abbirami Elangovan, Namakkal S. Rajasekaran, Sivasudha Thilagar
  Food Research International.2021; 140: 110081.     CrossRef
• Sex May Modulate the Effects of Combined Polyphenol Extract and L-citrulline Supplementation on Ambulatory Blood Pressure in Adults with Prehypertension: A Randomized Controlled Trial
  Cécile Vors, Maryka Rancourt-Bouchard, Charles Couillard, Iris Gigleux, Patrick Couture, Benoît Lamarche
  Nutrients.2021; 13(2): 399.     CrossRef
• Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury
  Wiramon Rungratanawanich, Ying Qu, Xin Wang, Musthafa Mohamed Essa, Byoung-Joon Song
  Experimental & Molecular Medicine.2021; 53(2): 168.     CrossRef
• Biological variation of glycated albumin, glucose and albumin in healthy Turkish subjects
  Osman Oğuz, Hilal Mercan, F. Sinem Hocaoglu-Emre
  Turkish Journal of Biochemistry.2021; 46(2): 197.     CrossRef
• Platelet Indices and Its Association with Microvascular Complications Among Type 2 Diabetes Mellitus Patients in Northeast Ethiopia: A Cross-Sectional Study
  Mitku Mammo Taderegew, Gashaw Garedew Woldeamanuel, Mamo Solomon Emeria, Melkamu Tilahun, Getachew Yideg Yitbarek, Betregiorgis Zegeye
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 865.     CrossRef
• Protective role of Clitoria ternatea L. flower extract on methylglyoxal-induced protein glycation and oxidative damage to DNA
  Poramin Chayaratanasin, Sirichai Adisakwattana, Thavaree Thilavech
  BMC Complementary Medicine and Therapies.2021;[Epub]     CrossRef
• Phytochemicals against anti‐diabetic complications: targeting the advanced glycation end product signaling pathway
  Amna Parveen, Razia Sultana, Seung Min Lee, Tae Hun Kim, Sun Yeou Kim
  Archives of Pharmacal Research.2021; 44(4): 378.     CrossRef
• Sesamin suppresses advanced glycation end products induced microglial reactivity using BV2 microglial cell line as a model
  Sasimol Udomruk, Benjawan Wudtiwai, Thuzar Hla Shwe, Thanyaluck Phitak, Peraphan Pothacharoen, Mattabhorn Phimphilai, Prachya Kongtawelert
  Brain Research Bulletin.2021; 172: 190.     CrossRef
• The Role of Sarcopenic Obesity in Cancer and Cardiovascular Disease: A Synthesis of the Evidence on Pathophysiological Aspects and Clinical Implications
  Erika Aparecida Silveira, Rômulo Roosevelt da Silva Filho, Maria Claudia Bernardes Spexoto, Fahimeh Haghighatdoost, Nizal Sarrafzadegan, Cesar de Oliveira
  International Journal of Molecular Sciences.2021; 22(9): 4339.     CrossRef
• Pterostilbene prevents methylglyoxal-induced cytotoxicity in endothelial cells by regulating glyoxalase, oxidative stress and apoptosis
  Dan Tang, Wei Xiao, Wen-Ting Gu, Zhi-Tong Zhang, Shu-Hong Xu, Zhi-Quan Chen, You-Hua Xu, Lu-Yong Zhang, Shu-Mei Wang, Hong Nie
  Food and Chemical Toxicology.2021; 153: 112244.     CrossRef
• Therapeutic Potential of Polyphenols in the Management of Diabetic Neuropathy
  Md. Tanvir Kabir, Nuzhat Tabassum, Md. Sahab Uddin, Faissal Aziz, Tapan Behl, Bijo Mathew, Md. Habibur Rahman, Raushanara Akter, Abdur Rauf, Lotfi Aleya, Rajeev K Singla
  Evidence-Based Complementary and Alternative Medicine.2021; 2021: 1.     CrossRef
• EndMT Regulation by Small RNAs in Diabetes-Associated Fibrotic Conditions: Potential Link With Oxidative Stress
  Roberta Giordo, Yusra M. A. Ahmed, Hilda Allam, Salah Abusnana, Lucia Pappalardo, Gheyath K. Nasrallah, Arduino Aleksander Mangoni, Gianfranco Pintus
  Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
• Novel advances in inhibiting advanced glycation end product formation using natural compounds
  Qinghe Song, Junjun Liu, Liyuan Dong, Xiaolei Wang, Xiandang Zhang
  Biomedicine & Pharmacotherapy.2021; 140: 111750.     CrossRef
• Inhibitory effect of Salvia coccinea on inflammatory responses through NF-κB signaling pathways in THP-1 cells and acute rat diabetes mellitus
  Arun Sudaramoorthy, Gobinath Shanmugam, Narkunaraja Shanmugam
  Acta Histochemica.2021; 123(5): 151735.     CrossRef
• The effects of different accumulated pressure-time integral stimuli on plantar blood flow in people with diabetes mellitus
  Yijie Duan, Weiyan Ren, Liqiang Xu, Wenqiang Ye, Yih-Kuen Jan, Fang Pu
  BMC Musculoskeletal Disorders.2021;[Epub]     CrossRef
• Piperine exhibits preventive and curative effect on erythrocytes membrane modifications and oxidative stress against in vitro albumin glycation
  Rashmi S. Tupe, Nilima Bangar, Akib Nisar, Amruta Kulkarni, Neena Sankhe, Rohan Chauhan, Nidhi Mistry, Shamim Shaikh
  Journal of Food Biochemistry.2021;[Epub]     CrossRef
• An Integrated Peptidomics and In Silico Approach to Identify Novel Anti-Diabetic Peptides in Parmigiano-Reggiano Cheese
  Serena Martini, Lisa Solieri, Alice Cattivelli, Valentina Pizzamiglio, Davide Tagliazucchi
  Biology.2021; 10(6): 563.     CrossRef
• The Effect of Dietary Supplements on Oxidative Stress in Pregnant Women with Gestational Diabetes Mellitus: A Network Meta-Analysis
  Christos Chatzakis, Alexandros Sotiriadis, Evangelia Tsakmaki, Maria Papagianni, George Paltoglou, Konstantinos Dinas, George Mastorakos
  Nutrients.2021; 13(7): 2284.     CrossRef
• Hydroxytyrosol Selectively Affects Non-Enzymatic Glycation in Human Insulin and Protects by AGEs Cytotoxicity
  Ivana Sirangelo, Margherita Borriello, Maria Liccardo, Marika Scafuro, Paola Russo, Clara Iannuzzi
  Antioxidants.2021; 10(7): 1127.     CrossRef
• Tinospora cordifolia activates PPARγ pathway and mitigates glomerular and tubular cell injury in diabetic kidney disease
  Vikram Patial, Swati Katoch, Jyoti Chhimwal, Prithvi Pal Singh, Patil Shivprasad Suresh, Yogendra Padwad
  Phytomedicine.2021; 91: 153663.     CrossRef
• Phloroglucinol prevents albumin glycation as well as diminishes ROS production, glycooxidative damage, nitrosative stress and inflammation in hepatocytes treated with high glucose
  Krzysztof Drygalski, Eliza Fereniec, Anna Zalewska, Adam Krętowski, Małgorzata Żendzian-Piotrowska, Mateusz Maciejczyk
  Biomedicine & Pharmacotherapy.2021; 142: 111958.     CrossRef
• Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis
  Durai Sellegounder, Parisa Zafari, Misagh Rajabinejad, Mahdi Taghadosi, Pankaj Kapahi
  International Immunopharmacology.2021; 98: 107806.     CrossRef
• Phytochemical Composition, Antiglycation, Antioxidant Activity and Methylglyoxal-Trapping Action of Brassica Vegetables
  Thavaree Thilavech, Marisa Marnpae, Kittana Mäkynen, Sirichai Adisakwattana
  Plant Foods for Human Nutrition.2021; 76(3): 340.     CrossRef
• Chlorophytum alismifolium mitigates microvascular complications of type 2 diabetes mellitus: the involvement of oxidative stress and aldose reductase
  Abdulhakim Abubakar, Abdullahi Balarabe Nazifi, Idris Mohammed Maje, Yusuf Tanko, Joseph Akpojo Anuka, Ezzeldin Mukthar Abdurahman
  Drug Metabolism and Personalized Therapy.2021;[Epub]     CrossRef
• Dietary advanced glycation end-products elicit toxicological effects by disrupting gut microbiome and immune homeostasis
  Yingjia Chen, Tai L. Guo
  Journal of Immunotoxicology.2021; 18(1): 93.     CrossRef
• Antioxidant compounds of Kielmeyera coriacea Mart. with α-amylase, lipase and advanced glycation end-product inhibitory activities
  Allisson Benatti Justino, Eder C. Santana, Rodrigo Rodrigues Franco, Julia Silveira Queiroz, Heitor Cappato Guerra Silva, Joed Pires de Lima, André Lopes Saraiva, Mário Machado Martins, Sérgio Antônio Lemos de Morais, Alberto de Oliveira, Luiz Ricardo Gou
  Journal of Pharmaceutical and Biomedical Analysis.2021; 206: 114387.     CrossRef
• Association of Novel Advanced Glycation End-Product (AGE10) with Complications of Diabetes as Measured by Enzyme-Linked Immunosorbent Assay
  Agnieszka Bronowicka-Szydełko, Małgorzata Krzystek-Korpacka, Małgorzata Gacka, Jadwiga Pietkiewicz, Urszula Jakobsche-Policht, Andrzej Gamian
  Journal of Clinical Medicine.2021; 10(19): 4499.     CrossRef
• Glycyrrhizic Acid Scavenges Reactive Carbonyl Species and Attenuates Glycation‐Induced Multiple Protein Modification: An In Vitro and In Silico Study
  Sahir Sultan Alvi, Rabia Nabi, Mohd. Shahnawaz Khan, Firoz Akhter, Saheem Ahmad, M. Salman Khan, Carla Tatone
  Oxidative Medicine and Cellular Longevity.2021;[Epub]     CrossRef
• Effects of Psoralea corylifolia L. seed extract on AGEs‑induced cell proliferation and fibrotic factor expression in mesangial cells
  Hyunah Chung, Eunhui Seo, Hee-Sook Jun
  Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
• Skin Autofluorescence as a Novel and Noninvasive Technology for Advanced Glycation End Products in Diabetic Foot Ulcers: A Systematic Review and Meta-analysis
  Seshadri Reddy Varikasuvu, Saurabh Varshney, Harish Sulekar
  Advances in Skin & Wound Care.2021; 34(11): 1.     CrossRef
• Characterization of the Oral Microbiome Among Children With Type 1 Diabetes Compared With Healthy Children
  Moti Moskovitz, Mira Nassar, Nadav Moriel, Avital Cher, Sarit Faibis, Diana Ram, David Zangen, Moran Yassour, Doron Steinberg
  Frontiers in Microbiology.2021;[Epub]     CrossRef
• Methylglyoxal-Derived Advanced Glycation End Products (AGE4) Promote Cell Proliferation and Survival in Renal Cell Carcinoma Cells through the RAGE/Akt/ERK Signaling Pathways
  Han-Kyul Nam, So-Ra Jeong, Min Cheol Pyo, Sang-Keun Ha, Mi-Hyun Nam, Kwang-Won Lee
  Biological and Pharmaceutical Bulletin.2021; 44(11): 1697.     CrossRef
• A Tale of Two Bioconjugations: pH Controlled Divergent Reactivity of Protein α-oxo-Aldehydes in Competing α-oxo-Mannich and Catalyst-Free Aldol Ligations
  Tessa Keenan, Richard J. Spears, Saeed Akkad, Clare S. Mahon, Natasha E. Hatton, Julia Walton, Amanda Noble, Nicholas D. Yates, Christoph G. Baumann, Alison Parkin, Nathalie Signoret, Martin A. Fascione
  ACS Chemical Biology.2021; 16(11): 2387.     CrossRef
• Skin Advanced Glycation End Products among Subjects with Type 2 Diabetes Mellitus with or without Distal Sensorimotor Polyneuropathy
  Stella Papachristou, Kalliopi Pafili, Grigorios Trypsianis, Dimitrios Papazoglou, Konstantinos Vadikolias, Nikolaos Papanas, Bernd Stratmann
  Journal of Diabetes Research.2021; 2021: 1.     CrossRef
• Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes
  Kyuho Kim, Tae Jung Oh, Hyen Chung Cho, Yun Kyung Lee, Chang Ho Ahn, Bo Kyung Koo, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang
  Scientific Reports.2021;[Epub]     CrossRef
• Isolation of Anti-Diabetic Active Compounds from Benincasae Exocarpium and Development of Simultaneous Analysis by HPLC-PDA
  Hye Sung Ryu, Suk Jin Lee, Wan Kyunn Whang
  Molecules.2021; 27(1): 9.     CrossRef
• Association of Oxidative Stress Markers with Vascular Stiffness Parameters in Patients with Diabetic Neuropathy
  Dominika Mačáková, Markéta Plchová, Lubica Cibičková, Ondřej Krystyník, David Karásek, Josef Zadrazil
  BioMed.2021; 2(1): 1.     CrossRef
• Gly-LysPred: Identification of Lysine Glycation Sites in Protein Using Position Relative Features and Statistical Moments Via Chou’s 5 Step Rule
  Shaheena Khanum, Muhammad Adeel Ashraf, Asim Karim, Bilal Shoaib, Muhammad Adnan Khan, Rizwan Ali Naqvi, Kamran Siddique, Mohammed Alswaitti
  Computers, Materials & Continua.2021; 66(2): 2165.     CrossRef
• Multiple fingerprint profiling for quality evaluation of polysaccharides and related biological activity analysis of Chinese patent drugs: Zishen Yutai Pills as a case study
  Hongyi Li, Jiliang Cao, Xu Wu, Yun Deng, Na Ning, Chunxian Geng, Ting Lei, Ruizhen Lin, Dingtao Wu, Shengpeng Wang, Peng Li, Yitao Wang
  Journal of Ethnopharmacology.2020; 260: 113045.     CrossRef
• Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes
  Jee Hee Yoo, Min Sun Choi, Jiyeon Ahn, Sung Woon Park, Yejin Kim, Kyu Yeon Hur, Sang-Man Jin, Gyuri Kim, Jae Hyeon Kim
  Diabetes Technology & Therapeutics.2020; 22(10): 768.     CrossRef
• Dimethyl fumarate ameliorates diabetes-associated vascular complications through ROS-TXNIP-NLRP3 inflammasome pathway
  Fatma M. Amin, Rania R. Abdelaziz, Mohamed F. Hamed, Manar A. Nader, George S.G. Shehatou
  Life Sciences.2020; 256: 117887.     CrossRef
• Aliskiren – A promising antioxidant agent beyond hypertension reduction
  Saeed Alshahrani
  Chemico-Biological Interactions.2020; 326: 109145.     CrossRef
• Glycation of fibronectin inhibits VEGF‐induced angiogenesis by uncoupling VEGF receptor‐2‐c‐Src crosstalk
  Tangting Chen, Jinling Dong, Haiyan Zhou, Xin Deng, Rong Li, Ni Chen, Mao Luo, Yongjie Li, Jianbo Wu, Liqun Wang
  Journal of Cellular and Molecular Medicine.2020; 24(16): 9154.     CrossRef
• Association between carbonyl stress markers and the risk of acute coronary syndrome in patients with type 2 diabetes mellitus–A pilot study
  Sushmita Bora, Prashant S. Adole, Nissy Motupalli, Vinay R. Pandit, Kolar V. Vinod
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 1751.     CrossRef
• A biochemical & biophysical study on in-vitro anti-glycating potential of iridin against d-Ribose modified BSA
  Rabia Nabi, Sahir Sultan Alvi, Mohammad Shafi Shah, Saheem Ahmad, Mohammad Faisal, Abdulrahman A. Alatar, M. Salman Khan
  Archives of Biochemistry and Biophysics.2020; 686: 108373.     CrossRef
• Esculin reduces P2X7 and reverses mitochondrial dysfunction in the renal cortex of diabetic rats
  R.S. Serralha, I.F. Rodrigues, A. Bertolini, D.Y. Lima, M. Nascimento, M.G. Mouro, G.R. Punaro, I. Visoná, A.M. Rodrigues, E.M.S. Higa
  Life Sciences.2020; 254: 117787.     CrossRef
• Mitochondrial Alterations and Enhanced Human Leukocyte/Endothelial Cell Interactions in Type 1 Diabetes
  Francesca Iannantuoni, Aranzazu M. de Marañon, Zaida Abad-Jiménez, Francisco Canet, Pedro Díaz-Pozo, Sandra López-Domènech, Carlos Morillas, Milagros Rocha, Víctor M. Víctor
  Journal of Clinical Medicine.2020; 9(7): 2155.     CrossRef
• Comparative Evaluation of Dental Implant Failure among Healthy and Well-Controlled Diabetic Patients—A 3-Year Retrospective Study
  Mohammed Ghazi Sghaireen, Abdulrahman A. Alduraywish, Kumar Chandan Srivastava, Deepti Shrivastava, Santosh R Patil, Selham Al Habib, May Hamza, Saifulizan Ab Rahman, Edward Lynch, Mohammad Khursheed Alam
  International Journal of Environmental Research and Public Health.2020; 17(14): 5253.     CrossRef
• Allithiamine Alleviates Hyperglycaemia-Induced Endothelial Dysfunction
  Attila Biró, Arnold Markovics, Mónika Éva Fazekas, Gábor Fidler, Gábor Szalóki, Melinda Paholcsek, János Lukács, László Stündl, Judit Remenyik
  Nutrients.2020; 12(6): 1690.     CrossRef
• Endothelial Dysfunction in Diabetic Retinopathy
  Fu Gui, Zhipeng You, Shuhua Fu, Hongxi Wu, Yulan Zhang
  Frontiers in Endocrinology.2020;[Epub]     CrossRef
• Diabetes affects endothelial cell function and alters fibrin clot formation in a microvascular flow model: A pilot study
  Lorenz Jenny, Andreas Melmer, Markus Laimer, Elaissa T Hardy, Wilbur A Lam, Verena Schroeder
  Diabetes and Vascular Disease Research.2020; 17(1): 147916412090304.     CrossRef
• Measures of lung function and their relationship with advanced glycation end-products
  Suneela Zaigham, Margaretha Persson, Amra Jujic, Sophia Frantz, Yan Borné, Andrei Malinovschi, Per Wollmer, Gunnar Engström
  ERJ Open Research.2020; 6(2): 00356-2019.     CrossRef
• LSEC model of aging
  Laurent Grosse, Dmitry V. Bulavin
  Aging.2020; 12(11): 11152.     CrossRef
• Mitochondrial superoxide/hydrogen peroxide: An emerging therapeutic target for metabolic diseases
  Jialong Yan, Jinyong Jiang, Lu He, Linxi Chen
  Free Radical Biology and Medicine.2020; 152: 33.     CrossRef
• Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
  Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
  Medicine.2020; 99(33): e21038.     CrossRef
• Cognitive impairments in type 2 diabetes, risk factors and preventive strategies
  Garima Sharma, Arti Parihar, Tanay Talaiya, Kirti Dubey, Bhagyesh Porwal, Mordhwaj S. Parihar
  Journal of Basic and Clinical Physiology and Pharmacology.2020;[Epub]     CrossRef
• Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
  Chan-Hee Jung, Ji-Oh Mok
  Endocrinology and Metabolism.2020; 35(2): 260.     CrossRef
• Pathophysiology of atherosclerosis: Association of risk factors and treatment strategies using plant‐based bioactive compounds
  Hina Sharif, Muhammad Sajid Hamid Akash, Kanwal Rehman, Kanwal Irshad, Imran Imran
  Journal of Food Biochemistry.2020;[Epub]     CrossRef
• Purification and identification of buckwheat hull flavonoids and its comparative evaluation on antioxidant and cytoprotective activity in vitro
  Yang Cui, Ziying Zhao, Ziqi Liu, Junmei Liu, Chunhong Piao, Dailin Liu
  Food Science & Nutrition.2020; 8(7): 3882.     CrossRef
• Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications
  Eleftheria Papachristoforou, Vaia Lambadiari, Eirini Maratou, Konstantinos Makrilakis, Celestino Sardu
  Journal of Diabetes Research.2020; 2020: 1.     CrossRef
• Comparing the incidence of major cardiovascular events and severe microvascular complications in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
  Ying-Ying Zhu, Zu-Yao Yang, Ping Li, Xin-Ying Huang, Xue-Hong Zhang, Li-Nong Ji, Jin-Ling Tang
  World Journal of Meta-Analysis.2020; 8(5): 400.     CrossRef
• Influence of melatonin on the kidneys of rats with experimental diabetes mellitus type 2
  A. V. Semenko, Y. V. Murdasov, S. V. Kirichenko, V. I. Zhyliuk, G. A. Ushakovа
  Regulatory Mechanisms in Biosystems.2020; 11(3): 384.     CrossRef
• Diabetes and cardiovascular disease: inter-relation of risk factors and treatment
  Aman Sharma, Shweta Mittal, Rohan Aggarwal, Meenakshi K. Chauhan
  Future Journal of Pharmaceutical Sciences.2020;[Epub]     CrossRef
• In Vitro Antioxidant and Anti-Glycation Activity of Resveratrol and Its Novel Triester with Trolox
  Sebastiano Intagliata, Angelo Spadaro, Miriam Lorenti, Annamaria Panico, Edy A. Siciliano, Sabrina Barbagallo, Benito Macaluso, Shyam H. Kamble, Maria N. Modica, Lucia Montenegro
  Antioxidants.2020; 10(1): 12.     CrossRef
• Blood–Nerve Barrier (BNB) Pathology in Diabetic Peripheral Neuropathy and In Vitro Human BNB Model
  Yukio Takeshita, Ryota Sato, Takashi Kanda
  International Journal of Molecular Sciences.2020; 22(1): 62.     CrossRef
• Prediction of Antiglycation Activity by Calculating the Energies of Frontier Molecular Orbitals for New 4-Hydroxy-1,4-Dihydroazolo[5,1-c]-1,2,4-Triazines Used as an Example
  R. A. Litvinov, R. A. Drokin, D. D. Shamshina, M. Yu. Kalenova, L. E. Usmianova, E. A. Muraveva, P. M. Vasiliev, E. K. Voinkov, E. N. Ulomskiy, A. A. Spasov, V. L. Rusinov
  Russian Journal of Bioorganic Chemistry.2020; 46(6): 1278.     CrossRef
• Obesity and Comorbidity: Could Simultaneous Targeting of esRAGE and sRAGE Be the Panacea?
  Chinedum Eleazu, Norsuhana Omar, Oon Zhi Lim, Boon Seng Yeoh, Nik Hazlina Nik Hussain, Mahaneem Mohamed
  Frontiers in Physiology.2019;[Epub]     CrossRef
• Glucose Variability and Coronary Artery Disease
  Jinggang Xia, Chunlin Yin
  Heart, Lung and Circulation.2019; 28(4): 553.     CrossRef
• Recent advances in the pathogenesis of microvascular complications in diabetes
  Sungmi Park, Hyeon-Ji Kang, Jae-Han Jeon, Min-Ji Kim, In-Kyu Lee
  Archives of Pharmacal Research.2019; 42(3): 252.     CrossRef
• Advanced Glycation End Products (AGEs) May Be a Striking Link Between Modern Diet and Health
  Vidhu Gill, Vijay Kumar, Kritanjali Singh, Ashok Kumar, Jong-Joo Kim
  Biomolecules.2019; 9(12): 888.     CrossRef
• DeepGly: A Deep Learning Framework With Recurrent and Convolutional Neural Networks to Identify Protein Glycation Sites From Imbalanced Data
  Jingui Chen, Runtao Yang, Chengjin Zhang, Lina Zhang, Qian Zhang
  IEEE Access.2019; 7: 142368.     CrossRef
• Lysophosphatidic Acid Signaling in Diabetic Nephropathy
  Jong Lee, Donghee Kim, Yoon Oh, Hee-Sook Jun
  International Journal of Molecular Sciences.2019; 20(11): 2850.     CrossRef
• Vascular Inflammation Risk Factors in Retinal Disease
  Ileana Soto, Mark P. Krebs, Alaina M. Reagan, Gareth R. Howell
  Annual Review of Vision Science.2019; 5(1): 99.     CrossRef
• Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences
  Domenico Sergi, Justine Renaud, Nicola Simola, Maria-Grazia Martinoli
  Frontiers in Aging Neuroscience.2019;[Epub]     CrossRef
• Advanced Glycation End Products Are Associated With Inflammation and Endothelial Dysfunction in HIV
  Vanessa El Kamari, Alicia Thomas, Lingpeng Shan, Abdus Sattar, Vincent Monnier, Scott K. Howell, Paul J. Beisswenger, Grace A. McComsey
  JAIDS Journal of Acquired Immune Deficiency Syndromes.2019; 81(2): e55.     CrossRef
• 1,25-(OH)2D3 protects Schwann cells against advanced glycation end products-induced apoptosis through PKA-NF-κB pathway
  Shiqing Xu, Jing Li, Min Zhai, Xiaoqi Yao, Honglin Liu, Tingting Deng, Hanqing Cai, Wan Zhang, Wenjian Zhang, Jinning Lou, Liang Peng
  Life Sciences.2019; 225: 107.     CrossRef
• Maize bran feruloylated oligosaccharides inhibited AGEs formation in glucose/amino acids and glucose/BSA models
  Junqing Huang, Jiayi Ren, Gabriel Tao, Yongsheng Chen, Shengwen Yao, Duoduo Han, Ruixia Qiu
  Food Research International.2019; 122: 443.     CrossRef
• Endothelial cell-derived small extracellular vesicles suppress cutaneous wound healing through regulating fibroblasts autophagy
  Tingting Zeng, Xiaoyi Wang, Wei Wang, Qiling Feng, Guojuan Lao, Ying Liang, Chuan Wang, Jing Zhou, Yuying Chen, Jing Liu, Haiqi Gao, Biyun Lan, Yuxi Wu, Yuting Han, Yanyan Liu, Hongxing Chen, Liyi Liu, Chuan Yang, Li Yan, Meng Ren, Kan Sun
  Clinical Science.2019;[Epub]     CrossRef
• Almond-supplemented diet improves sexual functions beyond Phosphodiesterase-5 inhibition in diabetic male rats
  Adeniyi A. Adebayo, Ganiyu Oboh, Ayokunle O. Ademosun
  Heliyon.2019; 5(12): e03035.     CrossRef
• Functional and Structural Changes of the Blood-Nerve-Barrier in Diabetic Neuropathy
  Mette Richner, Nelson Ferreira, Anete Dudele, Troels S. Jensen, Christian B. Vaegter, Nádia P. Gonçalves
  Frontiers in Neuroscience.2019;[Epub]     CrossRef
• Tocotrienol-rich vitamin E improves diabetic nephropathy and persists 6–9 months after washout: a phase IIa randomized controlled trial
  Gerald Chen Jie Tan, Suzanne May Quinn Tan, Sonia Chew Wen Phang, Yeek Tat Ng, En Yng Ng, Badariah Ahmad, Uma Devi M. Palamisamy, Khalid Abdul Kadir
  Therapeutic Advances in Endocrinology and Metabolism.2019;[Epub]     CrossRef
• Dietary Advanced Glycation End Products: Digestion, Metabolism and Modulation of Gut Microbial Ecology
  Matthew Snelson, Melinda Coughlan
  Nutrients.2019; 11(2): 215.     CrossRef
• Degradation of Peptide-Bound Maillard Reaction Products in Gastrointestinal Digests of Glyoxal-Glycated Casein by Human Colonic Microbiota
  Dan Xu, Lin Li, Xia Zhang, Hong Yao, Mingquan Yang, Zuoqi Gai, Bing Li, Di Zhao
  Journal of Agricultural and Food Chemistry.2019; 67(43): 12094.     CrossRef
• Targeting inflammation in diabetic nephropathy: a tale of hope
  Juan Antonio Moreno, Carmen Gomez-Guerrero, Sebastian Mas, Ana Belen Sanz, Oscar Lorenzo, Marta Ruiz-Ortega, Lucas Opazo, Sergio Mezzano, Jesus Egido
  Expert Opinion on Investigational Drugs.2018; 27(11): 917.     CrossRef
• Red Meat Consumption (Heme Iron Intake) and Risk for Diabetes and Comorbidities?
  Ranjita Misra, Padmini Balagopal, Sudha Raj, Thakor G. Patel
  Current Diabetes Reports.2018;[Epub]     CrossRef

About this article

Rhee SY, Kim YS. The Role of Advanced Glycation End Products in Diabetic Vascular Complications. Diabetes Metab J. 2018;42(3):188-195.

Received: Dec 27, 2017; Accepted: Mar 29, 2018

DOI: https://doi.org/10.4093/dmj.2017.0105.

Download citation ↓